Alnylam Pharmaceuticals, Inc. announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination for patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Through complementary initiatives with Viz.ai and the American Heart Association, Alnylam is advancing a comprehensive, system-level approach to address persistent challenges of underdiagnosis and fragmented care in ATTR-CM. Alnylam is partnering with Viz.ai, the leader in artificial intelligence (AI)-powered disease detection and care coordination, to develop an AI-enabled ATTR-CM care pathway designed to help clinicians identify patients earlier in the course of disease and guide appropriate diagnostic evaluation and referral.
The pathway combines a U.S. Food and Drug Administration (FDA)-cleared echocardiography AI algorithm, Us2.ai, with electronic health record connectivity and integration into routine clinical practice to support earlier recognition of ATTR-CM and facilitate coordinated care across cardiology and heart failure teams. The collaboration includes the AI-Enhanced Echocardiography Workflow to Advance Recognition and Diagnosis of Cardiac Amyloidosis (AWARE) study ? one of the first multi-system prospective implementation studies designed to evaluate how AI-enabled screening can be integrated into routine clinical workflows and assess its impact on diagnostic timelines, care coordination, and clinical decision-making in ATTR-CM. The AWARE study is intended to help address this barrier by evaluating practical approaches to integrating AI tools into existing care pathways.
The initiative will launch at five pilot health systems later this year, representing a diverse set of clinical settings, with the goal of generating real-world evidence to inform broader, scalable adoption across health systems in the Viz.ai network. Complementing AI-enabled diagnostic technology, Alnylam is supporting a national effort focused on strengthening systems of care for people living with ATTR-CM, led by the American Heart Association. The three-year initiative will convene a 10-site cohort of multidisciplinary health systems in a national learning collaborative designed to identify gaps in care, share best practices, and scale effective models for diagnosing and managing ATTR-CM.
Participating centers will evaluate current practice pathways across diagnosis, referral, treatment, and follow-up in order to improve coordinated care and optimize patient outcomes. Insights generated through the program will be disseminated nationally to help improve care delivery and outcomes for patients with ATTR-CM. This work will amplify proven, replicable models of excellence with the goal of enabling a stronger, more integrated system of care for patients nationwide.
Together, these efforts reflect Alnylam?s leadership in redefining how ATTR-CM is identified and managed, by shifting diagnosis earlier, strengthening care pathways, and enabling more consistent, coordinated care at scale. By investing in AI-enabled detection, real-world evidence, and system-level partnerships, Alnylam aims to address the root causes of underdiagnosis and fragmentation and help ensure that patients are identified at a point when intervention may make the greatest difference.
